Bargain, Value Trap or Something in Between?

Executive summary

Over the last decade, U.S. large cap growth stocks have been far and away the best performing major financial asset in the world. However, as most good contrarians know, the most attractive prospective investment opportunities rarely come from past winners, especially when they have been of this magnitude. In this piece we consider three notable relative equity market underperformers during U.S. growth’s triumphant run: U.S. value, U.S. small, and China. Specifically, we share four avenues of analysis we recommend for differentiating between those assets which are poised to rebound and those which are in danger of continuing to disappoint:

  1. Valuations – Do these stocks actually look cheap?
  2. Fundamental drivers of returns – Which sources of underperformance are likely to mean-revert (or not)?
  3. Changes in group characteristics – Have these groups of stocks become “junkier” or less profitable, which would justify lower fair value going forward?
  4. And finally, how should investors weigh structural forces that, whether or not they have impacted these groups to date, seem important to incorporate for evaluating future return potential?

Our analysis leads us to the following investment conclusions:

  • U.S. large value equities are very attractive today – in fact, they have almost never been cheaper relative to the overall market. Their poor trailing returns have primarily been driven by falling relative valuations, not by deterioration in their underlying businesses. We believe large value stocks are positioned to outperform, especially in long/short portfolios (such as our Equity Dislocation Strategy) where it is easier to control stock-specific risk.
  • U.S. small caps are also unusually inexpensive versus the market, but their falling relative valuation is partly deserved due to deteriorating profitability, increasing junkiness, and slowing growth (due to falling rates of IPOs and associated average business maturity). Given these headwinds, where we own U.S. small caps in our asset allocation portfolios we are oriented toward higher-quality businesses.
  • Chinese stock valuations appear mildly attractive versus their history and are the cheapest major market today. However, the most meaningful influence on their poor returns has been deteriorating fundamentals and significant shareholder dilution, not falling valuations. Weakening return on capital and quality metrics, along with significant geopolitical and regulatory risks, make us cautious on China. We consider emerging markets outside of China to be a better risk/reward trade-off.

The last decade’s performance

We will admit there is nothing particularly magical about starting our clock for selecting underperforming equity groups in the fall of 2014: the troubles for U.S. large value stocks predated that time, and those for U.S. small and China arguably started later. But 2014 was reasonably near the start of an extraordinary run for U.S. large growth stocks, a meteoric rise which has absolutely captivated the investing world. Since September 2014, U.S. large growth has delivered an annualized return of 12.4% real, more than twice both its long-run average and the return of the MSCI All Country World Index (of which it is a very substantial part).1 While during this period U.S. large value and U.S. small caps haven’t done especially badly – on an annualized basis U.S. large value (as defined by GMO) delivered 8.8% real 2 and U.S. small delivered 5.8% real – they gave the worst returns relative to their markets of any style groups.

Exhibit 1 shows the relative performance of various size and value factors within U.S., EAFE, and emerging markets over the last decade. While small caps did “ok” outside of the U.S., particularly in emerging markets, within the U.S., small lagged by a painful 4.4%/year. It is a reasonably well-known fact that nearly half of the underperformance of small versus large in the U.S. can be explained by the outperformance of the “Magnificent 7” stocks, but even if one were to exclude the 10 largest U.S. stocks from this analysis, U.S. small still trailed large by 2.5%/year, hence making our list of the “also-rans” featured in this paper.

exhibit 1